nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—NOS3—systemic scleroderma	0.384	1	CbGaD
Doxorubicin—XDH—Azathioprine—systemic scleroderma	0.0858	0.272	CbGbCtD
Doxorubicin—ABCG2—Leflunomide—systemic scleroderma	0.0358	0.113	CbGbCtD
Doxorubicin—ABCC10—Methotrexate—systemic scleroderma	0.0343	0.109	CbGbCtD
Doxorubicin—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0244	0.0775	CbGbCtD
Doxorubicin—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0221	0.0701	CbGbCtD
Doxorubicin—ABCC3—Methotrexate—systemic scleroderma	0.0216	0.0684	CbGbCtD
Doxorubicin—ABCB1—Lisinopril—systemic scleroderma	0.0135	0.0429	CbGbCtD
Doxorubicin—ABCC1—Methotrexate—systemic scleroderma	0.0132	0.042	CbGbCtD
Doxorubicin—ABCB1—Captopril—systemic scleroderma	0.0101	0.0321	CbGbCtD
Doxorubicin—ABCC2—Methotrexate—systemic scleroderma	0.0098	0.0311	CbGbCtD
Doxorubicin—CYP2D6—Captopril—systemic scleroderma	0.00953	0.0303	CbGbCtD
Doxorubicin—ABCG2—Methotrexate—systemic scleroderma	0.00886	0.0281	CbGbCtD
Doxorubicin—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00796	0.0253	CbGbCtD
Doxorubicin—NOS1—myenteric nerve plexus—systemic scleroderma	0.00788	0.103	CbGeAlD
Doxorubicin—ABCB1—Prednisone—systemic scleroderma	0.00637	0.0202	CbGbCtD
Doxorubicin—ABCC6—dermis—systemic scleroderma	0.0052	0.0683	CbGeAlD
Doxorubicin—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00477	0.0151	CbGbCtD
Doxorubicin—NOS3—pulmonary artery—systemic scleroderma	0.00424	0.0557	CbGeAlD
Doxorubicin—CYP3A4—Prednisone—systemic scleroderma	0.00381	0.0121	CbGbCtD
Doxorubicin—ABCB1—Methotrexate—systemic scleroderma	0.00319	0.0101	CbGbCtD
Doxorubicin—NOS3—umbilical vein—systemic scleroderma	0.0028	0.0368	CbGeAlD
Doxorubicin—NOS1—artery—systemic scleroderma	0.00207	0.0272	CbGeAlD
Doxorubicin—NOS1—endothelium—systemic scleroderma	0.00175	0.0229	CbGeAlD
Doxorubicin—NOS1—blood vessel—systemic scleroderma	0.00161	0.0212	CbGeAlD
Doxorubicin—NOS3—artery—systemic scleroderma	0.00157	0.0206	CbGeAlD
Doxorubicin—NOS2—tendon—systemic scleroderma	0.00156	0.0205	CbGeAlD
Doxorubicin—NOS3—endothelium—systemic scleroderma	0.00133	0.0174	CbGeAlD
Doxorubicin—AURKA—Mycophenolate mofetil—Mycophenolic acid—systemic scleroderma	0.00131	0.405	CbGdCrCtD
Doxorubicin—NOS3—blood vessel—systemic scleroderma	0.00122	0.0161	CbGeAlD
Doxorubicin—AKR1A1—smooth muscle tissue—systemic scleroderma	0.000997	0.0131	CbGeAlD
Doxorubicin—NDUFS7—connective tissue—systemic scleroderma	0.00099	0.013	CbGeAlD
Doxorubicin—AKR1A1—skin of body—systemic scleroderma	0.000984	0.0129	CbGeAlD
Doxorubicin—CBR3—tendon—systemic scleroderma	0.00097	0.0127	CbGeAlD
Doxorubicin—ABCB8—lung—systemic scleroderma	0.000884	0.0116	CbGeAlD
Doxorubicin—CBR3—lung—systemic scleroderma	0.000851	0.0112	CbGeAlD
Doxorubicin—NDUFS2—connective tissue—systemic scleroderma	0.000821	0.0108	CbGeAlD
Doxorubicin—NDUFS3—connective tissue—systemic scleroderma	0.000811	0.0106	CbGeAlD
Doxorubicin—AKR1A1—digestive system—systemic scleroderma	0.000787	0.0103	CbGeAlD
Doxorubicin—NOS1—smooth muscle tissue—systemic scleroderma	0.000755	0.00992	CbGeAlD
Doxorubicin—NDUFS2—smooth muscle tissue—systemic scleroderma	0.000751	0.00986	CbGeAlD
Doxorubicin—ABCC6—connective tissue—systemic scleroderma	0.000751	0.00986	CbGeAlD
Doxorubicin—AKR1A1—tendon—systemic scleroderma	0.000749	0.00984	CbGeAlD
Doxorubicin—AURKA—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.000743	0.229	CbGdCrCtD
Doxorubicin—NDUFS3—smooth muscle tissue—systemic scleroderma	0.000742	0.00974	CbGeAlD
Doxorubicin—NDUFS2—skin of body—systemic scleroderma	0.000741	0.00973	CbGeAlD
Doxorubicin—NDUFS3—skin of body—systemic scleroderma	0.000732	0.00961	CbGeAlD
Doxorubicin—NDUFS7—digestive system—systemic scleroderma	0.000715	0.00939	CbGeAlD
Doxorubicin—YWHAG—connective tissue—systemic scleroderma	0.000707	0.00928	CbGeAlD
Doxorubicin—DHCR7—skin of body—systemic scleroderma	0.000695	0.00913	CbGeAlD
Doxorubicin—NDUFS7—tendon—systemic scleroderma	0.000681	0.00894	CbGeAlD
Doxorubicin—AURKA—digestive system—systemic scleroderma	0.000665	0.00873	CbGeAlD
Doxorubicin—AKR1A1—lung—systemic scleroderma	0.000657	0.00863	CbGeAlD
Doxorubicin—YWHAG—smooth muscle tissue—systemic scleroderma	0.000646	0.00849	CbGeAlD
Doxorubicin—AURKA—tendon—systemic scleroderma	0.000633	0.00831	CbGeAlD
Doxorubicin—NOS3—connective tissue—systemic scleroderma	0.000628	0.00824	CbGeAlD
Doxorubicin—NDUFS7—lung—systemic scleroderma	0.000597	0.00785	CbGeAlD
Doxorubicin—NOS1—digestive system—systemic scleroderma	0.000596	0.00783	CbGeAlD
Doxorubicin—NDUFS2—digestive system—systemic scleroderma	0.000593	0.00778	CbGeAlD
Doxorubicin—NDUFS3—digestive system—systemic scleroderma	0.000585	0.00769	CbGeAlD
Doxorubicin—RALBP1—smooth muscle tissue—systemic scleroderma	0.000584	0.00767	CbGeAlD
Doxorubicin—NOS3—smooth muscle tissue—systemic scleroderma	0.000574	0.00754	CbGeAlD
Doxorubicin—NOS1—tendon—systemic scleroderma	0.000568	0.00745	CbGeAlD
Doxorubicin—NDUFS2—tendon—systemic scleroderma	0.000564	0.00741	CbGeAlD
Doxorubicin—NDUFS3—tendon—systemic scleroderma	0.000557	0.00732	CbGeAlD
Doxorubicin—DHCR7—digestive system—systemic scleroderma	0.000556	0.00731	CbGeAlD
Doxorubicin—AURKA—lung—systemic scleroderma	0.000555	0.00729	CbGeAlD
Doxorubicin—AKR1C3—smooth muscle tissue—systemic scleroderma	0.000538	0.00707	CbGeAlD
Doxorubicin—CBR1—skin of body—systemic scleroderma	0.000538	0.00706	CbGeAlD
Doxorubicin—YWHAG—digestive system—systemic scleroderma	0.00051	0.0067	CbGeAlD
Doxorubicin—NOS1—lung—systemic scleroderma	0.000498	0.00654	CbGeAlD
Doxorubicin—XDH—digestive system—systemic scleroderma	0.000498	0.00654	CbGeAlD
Doxorubicin—NDUFS2—lung—systemic scleroderma	0.000495	0.0065	CbGeAlD
Doxorubicin—NDUFS3—lung—systemic scleroderma	0.000489	0.00642	CbGeAlD
Doxorubicin—ABCB11—digestive system—systemic scleroderma	0.000486	0.00639	CbGeAlD
Doxorubicin—YWHAG—tendon—systemic scleroderma	0.000486	0.00638	CbGeAlD
Doxorubicin—NQO1—connective tissue—systemic scleroderma	0.000477	0.00627	CbGeAlD
Doxorubicin—DHCR7—lung—systemic scleroderma	0.000465	0.0061	CbGeAlD
Doxorubicin—RALBP1—digestive system—systemic scleroderma	0.000461	0.00605	CbGeAlD
Doxorubicin—NOS3—digestive system—systemic scleroderma	0.000453	0.00596	CbGeAlD
Doxorubicin—ABCC6—lung—systemic scleroderma	0.000453	0.00595	CbGeAlD
Doxorubicin—RALBP1—tendon—systemic scleroderma	0.000439	0.00576	CbGeAlD
Doxorubicin—NQO1—smooth muscle tissue—systemic scleroderma	0.000437	0.00573	CbGeAlD
Doxorubicin—NOS3—tendon—systemic scleroderma	0.000432	0.00567	CbGeAlD
Doxorubicin—NQO1—skin of body—systemic scleroderma	0.000431	0.00566	CbGeAlD
Doxorubicin—CBR1—digestive system—systemic scleroderma	0.00043	0.00565	CbGeAlD
Doxorubicin—YWHAG—lung—systemic scleroderma	0.000426	0.0056	CbGeAlD
Doxorubicin—CBR1—tendon—systemic scleroderma	0.00041	0.00538	CbGeAlD
Doxorubicin—AKR1C3—tendon—systemic scleroderma	0.000404	0.00531	CbGeAlD
Doxorubicin—RALBP1—lung—systemic scleroderma	0.000385	0.00506	CbGeAlD
Doxorubicin—NOS3—lung—systemic scleroderma	0.000379	0.00497	CbGeAlD
Doxorubicin—POR—tendon—systemic scleroderma	0.000369	0.00485	CbGeAlD
Doxorubicin—CBR1—lung—systemic scleroderma	0.000359	0.00472	CbGeAlD
Doxorubicin—AKR1C3—lung—systemic scleroderma	0.000355	0.00466	CbGeAlD
Doxorubicin—NOS1—Latent infection of Homo sapiens with Mycobacterium tuberculosis—NOS3—systemic scleroderma	0.000349	0.00767	CbGpPWpGaD
Doxorubicin—NOS2—Nitric oxide stimulates guanylate cyclase—NOS3—systemic scleroderma	0.000348	0.00764	CbGpPWpGaD
Doxorubicin—NQO1—digestive system—systemic scleroderma	0.000345	0.00453	CbGeAlD
Doxorubicin—TOP2A—tendon—systemic scleroderma	0.000344	0.00452	CbGeAlD
Doxorubicin—NOS3—Endothelin Pathways—EDN1—systemic scleroderma	0.000344	0.00755	CbGpPWpGaD
Doxorubicin—YWHAG—a6b1 and a6b4 Integrin signaling—IL1A—systemic scleroderma	0.000336	0.00737	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—SELP—systemic scleroderma	0.000335	0.00736	CbGpPWpGaD
Doxorubicin—CYP1B1—connective tissue—systemic scleroderma	0.000335	0.0044	CbGeAlD
Doxorubicin—NQO1—tendon—systemic scleroderma	0.000328	0.00431	CbGeAlD
Doxorubicin—POR—lung—systemic scleroderma	0.000324	0.00426	CbGeAlD
Doxorubicin—AKR1C3—Diseases associated with visual transduction—HSPG2—systemic scleroderma	0.000323	0.00708	CbGpPWpGaD
Doxorubicin—CBR3—NRF2 pathway—TGFB1—systemic scleroderma	0.000321	0.00705	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—RHOB—systemic scleroderma	0.000313	0.00687	CbGpPWpGaD
Doxorubicin—NOS1—Monoamine Transport—IL1B—systemic scleroderma	0.000312	0.00685	CbGpPWpGaD
Doxorubicin—ABCC3—digestive system—systemic scleroderma	0.000309	0.00406	CbGeAlD
Doxorubicin—ABCC10—digestive system—systemic scleroderma	0.000308	0.00404	CbGeAlD
Doxorubicin—CYP1B1—smooth muscle tissue—systemic scleroderma	0.000307	0.00403	CbGeAlD
Doxorubicin—CYP1B1—skin of body—systemic scleroderma	0.000303	0.00398	CbGeAlD
Doxorubicin—TOP2A—lung—systemic scleroderma	0.000302	0.00397	CbGeAlD
Doxorubicin—NOS2—Circadian rythm related genes—TOP1—systemic scleroderma	0.000297	0.00651	CbGpPWpGaD
Doxorubicin—ABCC10—tendon—systemic scleroderma	0.000293	0.00385	CbGeAlD
Doxorubicin—NQO1—lung—systemic scleroderma	0.000288	0.00378	CbGeAlD
Doxorubicin—AURKA—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000285	0.00626	CbGpPWpGaD
Doxorubicin—NOS2—IL23-mediated signaling events—CCL2—systemic scleroderma	0.000276	0.00607	CbGpPWpGaD
Doxorubicin—YWHAG—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.000266	0.00584	CbGpPWpGaD
Doxorubicin—NOS3—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP1—systemic scleroderma	0.000264	0.00579	CbGpPWpGaD
Doxorubicin—NOS2—Latent infection of Homo sapiens with Mycobacterium tuberculosis—NOS3—systemic scleroderma	0.000264	0.00579	CbGpPWpGaD
Doxorubicin—ABCC3—lung—systemic scleroderma	0.000258	0.00339	CbGeAlD
Doxorubicin—ABCC10—lung—systemic scleroderma	0.000257	0.00338	CbGeAlD
Doxorubicin—NOS2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000254	0.00559	CbGpPWpGaD
Doxorubicin—ABCC2—digestive system—systemic scleroderma	0.000247	0.00325	CbGeAlD
Doxorubicin—CYP1B1—digestive system—systemic scleroderma	0.000242	0.00318	CbGeAlD
Doxorubicin—CBR3—Fluorometholone—Mometasone—systemic scleroderma	0.00024	0.0741	CbGdCrCtD
Doxorubicin—ABCB1—blood vessel—systemic scleroderma	0.00024	0.00315	CbGeAlD
Doxorubicin—AURKA—Cell Cycle, Mitotic—CENPC—systemic scleroderma	0.000237	0.00519	CbGpPWpGaD
Doxorubicin—NOS3—ACE Inhibitor Pathway—TGFB1—systemic scleroderma	0.000236	0.00517	CbGpPWpGaD
Doxorubicin—ABCC2—tendon—systemic scleroderma	0.000235	0.00309	CbGeAlD
Doxorubicin—YWHAG—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000232	0.00508	CbGpPWpGaD
Doxorubicin—CYP1B1—tendon—systemic scleroderma	0.00023	0.00303	CbGeAlD
Doxorubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IL1A—systemic scleroderma	0.000227	0.00498	CbGpPWpGaD
Doxorubicin—CYP1B1—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000225	0.00493	CbGpPWpGaD
Doxorubicin—NOS3—Angiogenesis—MMP9—systemic scleroderma	0.000217	0.00476	CbGpPWpGaD
Doxorubicin—NOS3—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCL2—systemic scleroderma	0.000215	0.00471	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—CENPC—systemic scleroderma	0.000212	0.00464	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000211	0.00464	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—IL1A—systemic scleroderma	0.000211	0.00462	CbGpPWpGaD
Doxorubicin—NOS2—Type II interferon signaling (IFNG)—IL1B—systemic scleroderma	0.00021	0.0046	CbGpPWpGaD
Doxorubicin—NOS2—IL23-mediated signaling events—IL1B—systemic scleroderma	0.00021	0.0046	CbGpPWpGaD
Doxorubicin—CYP2B6—skin of body—systemic scleroderma	0.000208	0.00273	CbGeAlD
Doxorubicin—ABCC1—tendon—systemic scleroderma	0.000207	0.00272	CbGeAlD
Doxorubicin—NOS3—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—systemic scleroderma	0.000204	0.00448	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—TOP1—systemic scleroderma	0.000203	0.00445	CbGpPWpGaD
Doxorubicin—CYP1B1—lung—systemic scleroderma	0.000202	0.00266	CbGeAlD
Doxorubicin—CBR3—Triamcinolone—Mometasone—systemic scleroderma	0.000199	0.0612	CbGdCrCtD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000197	0.00433	CbGpPWpGaD
Doxorubicin—NOS3—Plasma membrane estrogen receptor signaling—MMP2—systemic scleroderma	0.000188	0.00413	CbGpPWpGaD
Doxorubicin—CBR3—Fluocinolone Acetonide—Mometasone—systemic scleroderma	0.000183	0.0563	CbGdCrCtD
Doxorubicin—ABCC1—lung—systemic scleroderma	0.000182	0.00239	CbGeAlD
Doxorubicin—NOS2—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.000181	0.00397	CbGpPWpGaD
Doxorubicin—NOS1—Platelet homeostasis—NOS3—systemic scleroderma	0.00018	0.00395	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—CENPC—systemic scleroderma	0.000179	0.00394	CbGpPWpGaD
Doxorubicin—NOS3—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000172	0.00377	CbGpPWpGaD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000168	0.00368	CbGpPWpGaD
Doxorubicin—CYP2B6—digestive system—systemic scleroderma	0.000166	0.00218	CbGeAlD
Doxorubicin—NOS2—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000166	0.00363	CbGpPWpGaD
Doxorubicin—NOS3—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.00016	0.00352	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—CENPC—systemic scleroderma	0.00016	0.00352	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—IL1A—systemic scleroderma	0.000159	0.00349	CbGpPWpGaD
Doxorubicin—NOS2—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000155	0.0034	CbGpPWpGaD
Doxorubicin—NOS3—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—systemic scleroderma	0.000153	0.00337	CbGpPWpGaD
Doxorubicin—NOS1—Alzheimers Disease—IL1B—systemic scleroderma	0.000151	0.00332	CbGpPWpGaD
Doxorubicin—ABCG2—lung—systemic scleroderma	0.000151	0.00198	CbGeAlD
Doxorubicin—AURKA—Cell Cycle, Mitotic—CENPA—systemic scleroderma	0.00015	0.0033	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000147	0.00322	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—CCL2—systemic scleroderma	0.000145	0.00318	CbGpPWpGaD
Doxorubicin—NOS2—IL12-mediated signaling events—IL1B—systemic scleroderma	0.000142	0.00313	CbGpPWpGaD
Doxorubicin—AURKA—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000142	0.00312	CbGpPWpGaD
Doxorubicin—NOS3—Plasma membrane estrogen receptor signaling—MMP9—systemic scleroderma	0.000141	0.0031	CbGpPWpGaD
Doxorubicin—CYP2B6—lung—systemic scleroderma	0.000139	0.00182	CbGeAlD
Doxorubicin—NOS1—Hemostasis—SELP—systemic scleroderma	0.000139	0.00305	CbGpPWpGaD
Doxorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	0.000139	0.00304	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000137	0.003	CbGpPWpGaD
Doxorubicin—NOS2—Platelet homeostasis—NOS3—systemic scleroderma	0.000136	0.00298	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—CENPA—systemic scleroderma	0.000134	0.00295	CbGpPWpGaD
Doxorubicin—CBR3—Fluorometholone—Prednisone—systemic scleroderma	0.000131	0.0404	CbGdCrCtD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.00013	0.00286	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—RHOB—systemic scleroderma	0.00013	0.00284	CbGpPWpGaD
Doxorubicin—NOS3—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000129	0.00282	CbGpPWpGaD
Doxorubicin—CYP3A4—digestive system—systemic scleroderma	0.000126	0.00165	CbGeAlD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—CENPC—systemic scleroderma	0.000125	0.00275	CbGpPWpGaD
Doxorubicin—RALBP1—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000125	0.00275	CbGpPWpGaD
Doxorubicin—NOS2—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000124	0.00273	CbGpPWpGaD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000124	0.00273	CbGpPWpGaD
Doxorubicin—CYP2D6—digestive system—systemic scleroderma	0.000124	0.00162	CbGeAlD
Doxorubicin—XDH—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000118	0.00259	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—CSK—systemic scleroderma	0.000118	0.00259	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—CENPA—systemic scleroderma	0.000114	0.0025	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—CENPC—systemic scleroderma	0.000112	0.00246	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000111	0.00244	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—ITGAM—systemic scleroderma	0.000111	0.00243	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—IL1B—systemic scleroderma	0.00011	0.00241	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—CCL2—systemic scleroderma	0.000109	0.0024	CbGpPWpGaD
Doxorubicin—CBR3—Triamcinolone—Prednisone—systemic scleroderma	0.000108	0.0334	CbGdCrCtD
Doxorubicin—ABCG2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000106	0.00233	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—SELP—systemic scleroderma	0.000105	0.0023	CbGpPWpGaD
Doxorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	0.000104	0.00229	CbGpPWpGaD
Doxorubicin—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000104	0.00229	CbGpPWpGaD
Doxorubicin—NOS1—Myometrial Relaxation and Contraction Pathways—NOS3—systemic scleroderma	0.000104	0.00228	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000104	0.00228	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—MMP9—systemic scleroderma	0.000104	0.00227	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—CENPA—systemic scleroderma	0.000102	0.00223	CbGpPWpGaD
Doxorubicin—CBR3—Betamethasone—Mometasone—systemic scleroderma	9.82e-05	0.0303	CbGdCrCtD
Doxorubicin—CBR3—Dexamethasone—Mometasone—systemic scleroderma	9.82e-05	0.0303	CbGdCrCtD
Doxorubicin—NOS2—Hemostasis—RHOB—systemic scleroderma	9.77e-05	0.00214	CbGpPWpGaD
Doxorubicin—AURKA—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	9.75e-05	0.00214	CbGpPWpGaD
Doxorubicin—NOS3—AGE/RAGE pathway—MMP9—systemic scleroderma	9.66e-05	0.00212	CbGpPWpGaD
Doxorubicin—NOS3—Leptin signaling pathway—IL1B—systemic scleroderma	9.25e-05	0.00203	CbGpPWpGaD
Doxorubicin—XDH—Selenium Micronutrient Network—IL1B—systemic scleroderma	8.95e-05	0.00197	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—CSK—systemic scleroderma	8.9e-05	0.00195	CbGpPWpGaD
Doxorubicin—ABCB1—digestive system—systemic scleroderma	8.89e-05	0.00117	CbGeAlD
Doxorubicin—CBR1—NRF2 pathway—TGFB1—systemic scleroderma	8.86e-05	0.00195	CbGpPWpGaD
Doxorubicin—NOS1—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	8.83e-05	0.00194	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—TGFB1—systemic scleroderma	8.54e-05	0.00187	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—ITGAM—systemic scleroderma	8.37e-05	0.00184	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—IL1B—systemic scleroderma	8.29e-05	0.00182	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—HSPG2—systemic scleroderma	8.17e-05	0.00179	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—HSPG2—systemic scleroderma	8.17e-05	0.00179	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—SELP—systemic scleroderma	8.13e-05	0.00178	CbGpPWpGaD
Doxorubicin—NOS1—Disease—SMAD7—systemic scleroderma	8.11e-05	0.00178	CbGpPWpGaD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	8.06e-05	0.00177	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—CENPA—systemic scleroderma	7.96e-05	0.00175	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IL13—systemic scleroderma	7.84e-05	0.00172	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—MMP9—systemic scleroderma	7.82e-05	0.00172	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7.71e-05	0.00169	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—HSPG2—systemic scleroderma	7.69e-05	0.00169	CbGpPWpGaD
Doxorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—NOS3—systemic scleroderma	7.65e-05	0.00168	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—RHOB—systemic scleroderma	7.59e-05	0.00166	CbGpPWpGaD
Doxorubicin—ABCB1—lung—systemic scleroderma	7.43e-05	0.000975	CbGeAlD
Doxorubicin—NOS1—Disease—TGFBI—systemic scleroderma	7.41e-05	0.00163	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—CENPA—systemic scleroderma	7.12e-05	0.00156	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—SMAD7—systemic scleroderma	7.1e-05	0.00156	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—TGFB1—systemic scleroderma	7.07e-05	0.00155	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	6.95e-05	0.00153	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—CSK—systemic scleroderma	6.91e-05	0.00152	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—HSPG2—systemic scleroderma	6.53e-05	0.00143	CbGpPWpGaD
Doxorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	6.51e-05	0.00143	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—ITGAM—systemic scleroderma	6.5e-05	0.00143	CbGpPWpGaD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	6.48e-05	0.00142	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—TGFB1—systemic scleroderma	6.44e-05	0.00141	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	6.31e-05	0.00138	CbGpPWpGaD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	6.26e-05	0.00137	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—CTGF—systemic scleroderma	6.19e-05	0.00136	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—CTGF—systemic scleroderma	6.19e-05	0.00136	CbGpPWpGaD
Doxorubicin—NOS2—Disease—SMAD7—systemic scleroderma	6.11e-05	0.00134	CbGpPWpGaD
Doxorubicin—NOS3—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	6.1e-05	0.00134	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—HSPG2—systemic scleroderma	6.09e-05	0.00134	CbGpPWpGaD
Doxorubicin—NOS1—Disease—HSPG2—systemic scleroderma	5.91e-05	0.0013	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.84e-05	0.00128	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—CTGF—systemic scleroderma	5.82e-05	0.00128	CbGpPWpGaD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	5.73e-05	0.00126	CbGpPWpGaD
Doxorubicin—NOS1—Disease—CSK—systemic scleroderma	5.71e-05	0.00125	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—SMAD7—systemic scleroderma	5.62e-05	0.00123	CbGpPWpGaD
Doxorubicin—NOS2—Disease—TGFBI—systemic scleroderma	5.59e-05	0.00123	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—MMP1—systemic scleroderma	5.56e-05	0.00122	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—RHOB—systemic scleroderma	5.49e-05	0.00121	CbGpPWpGaD
Doxorubicin—NOS1—Disease—CD247—systemic scleroderma	5.37e-05	0.00118	CbGpPWpGaD
Doxorubicin—CBR3—Betamethasone—Prednisone—systemic scleroderma	5.35e-05	0.0165	CbGdCrCtD
Doxorubicin—CBR3—Dexamethasone—Prednisone—systemic scleroderma	5.35e-05	0.0165	CbGdCrCtD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.28e-05	0.00116	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	5.19e-05	0.00114	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—HSPG2—systemic scleroderma	5.18e-05	0.00114	CbGpPWpGaD
Doxorubicin—NOS3—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	5.17e-05	0.00114	CbGpPWpGaD
Doxorubicin—NQO1—NRF2 pathway—TGFB1—systemic scleroderma	5.17e-05	0.00114	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—TGFBI—systemic scleroderma	5.14e-05	0.00113	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.06e-05	0.00111	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CSK—systemic scleroderma	5e-05	0.0011	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—CTGF—systemic scleroderma	4.95e-05	0.00109	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	4.93e-05	0.00108	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	4.9e-05	0.00108	CbGpPWpGaD
Doxorubicin—NOS3—Disease—SMAD7—systemic scleroderma	4.75e-05	0.00104	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—CTGF—systemic scleroderma	4.62e-05	0.00101	CbGpPWpGaD
Doxorubicin—Anxiety—Mycophenolate mofetil—systemic scleroderma	4.59e-05	0.00026	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	4.58e-05	0.00026	CcSEcCtD
Doxorubicin—Hypersensitivity—Azathioprine—systemic scleroderma	4.57e-05	0.00026	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	4.57e-05	0.00026	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	4.57e-05	0.00026	CcSEcCtD
Doxorubicin—Insomnia—Lisinopril—systemic scleroderma	4.56e-05	0.000259	CcSEcCtD
Doxorubicin—Discomfort—Mycophenolate mofetil—systemic scleroderma	4.55e-05	0.000258	CcSEcCtD
Doxorubicin—Paraesthesia—Lisinopril—systemic scleroderma	4.52e-05	0.000257	CcSEcCtD
Doxorubicin—Vomiting—Captopril—systemic scleroderma	4.52e-05	0.000257	CcSEcCtD
Doxorubicin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	4.5e-05	0.000256	CcSEcCtD
Doxorubicin—Dyspnoea—Lisinopril—systemic scleroderma	4.49e-05	0.000255	CcSEcCtD
Doxorubicin—Rash—Captopril—systemic scleroderma	4.49e-05	0.000255	CcSEcCtD
Doxorubicin—Dermatitis—Captopril—systemic scleroderma	4.48e-05	0.000254	CcSEcCtD
Doxorubicin—Somnolence—Lisinopril—systemic scleroderma	4.48e-05	0.000254	CcSEcCtD
Doxorubicin—NOS2—Disease—HSPG2—systemic scleroderma	4.46e-05	0.000979	CbGpPWpGaD
Doxorubicin—Headache—Captopril—systemic scleroderma	4.46e-05	0.000253	CcSEcCtD
Doxorubicin—Confusional state—Mycophenolate mofetil—systemic scleroderma	4.45e-05	0.000253	CcSEcCtD
Doxorubicin—Dyspepsia—Lisinopril—systemic scleroderma	4.43e-05	0.000252	CcSEcCtD
Doxorubicin—Abdominal pain—Mycophenolic acid—systemic scleroderma	4.42e-05	0.000251	CcSEcCtD
Doxorubicin—Body temperature increased—Mycophenolic acid—systemic scleroderma	4.42e-05	0.000251	CcSEcCtD
Doxorubicin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	4.41e-05	0.000251	CcSEcCtD
Doxorubicin—Oedema—Mycophenolate mofetil—systemic scleroderma	4.41e-05	0.000251	CcSEcCtD
Doxorubicin—Asthma—Methotrexate—systemic scleroderma	4.4e-05	0.00025	CcSEcCtD
Doxorubicin—Infection—Mycophenolate mofetil—systemic scleroderma	4.39e-05	0.000249	CcSEcCtD
Doxorubicin—Decreased appetite—Lisinopril—systemic scleroderma	4.38e-05	0.000249	CcSEcCtD
Doxorubicin—Eosinophilia—Methotrexate—systemic scleroderma	4.35e-05	0.000247	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	4.35e-05	0.000247	CcSEcCtD
Doxorubicin—Fatigue—Lisinopril—systemic scleroderma	4.34e-05	0.000247	CcSEcCtD
Doxorubicin—Shock—Mycophenolate mofetil—systemic scleroderma	4.34e-05	0.000246	CcSEcCtD
Doxorubicin—NOS3—Disease—TGFBI—systemic scleroderma	4.34e-05	0.000953	CbGpPWpGaD
Doxorubicin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	4.33e-05	0.000246	CcSEcCtD
Doxorubicin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	4.32e-05	0.000245	CcSEcCtD
Doxorubicin—Hypersensitivity—Leflunomide—systemic scleroderma	4.32e-05	0.000245	CcSEcCtD
Doxorubicin—Pancreatitis—Methotrexate—systemic scleroderma	4.31e-05	0.000245	CcSEcCtD
Doxorubicin—Pain—Lisinopril—systemic scleroderma	4.31e-05	0.000245	CcSEcCtD
Doxorubicin—Constipation—Lisinopril—systemic scleroderma	4.31e-05	0.000245	CcSEcCtD
Doxorubicin—Tachycardia—Mycophenolate mofetil—systemic scleroderma	4.31e-05	0.000245	CcSEcCtD
Doxorubicin—NOS2—Disease—CSK—systemic scleroderma	4.31e-05	0.000946	CbGpPWpGaD
Doxorubicin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	4.29e-05	0.000243	CcSEcCtD
Doxorubicin—Bradycardia—Prednisone—systemic scleroderma	4.29e-05	0.000243	CcSEcCtD
Doxorubicin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	4.27e-05	0.000242	CcSEcCtD
Doxorubicin—Diarrhoea—Azathioprine—systemic scleroderma	4.25e-05	0.000241	CcSEcCtD
Doxorubicin—Haemoglobin—Prednisone—systemic scleroderma	4.23e-05	0.00024	CcSEcCtD
Doxorubicin—Nausea—Captopril—systemic scleroderma	4.23e-05	0.00024	CcSEcCtD
Doxorubicin—Haemorrhage—Prednisone—systemic scleroderma	4.21e-05	0.000239	CcSEcCtD
Doxorubicin—Anorexia—Mycophenolate mofetil—systemic scleroderma	4.21e-05	0.000239	CcSEcCtD
Doxorubicin—Asthenia—Leflunomide—systemic scleroderma	4.21e-05	0.000239	CcSEcCtD
Doxorubicin—NOS2—Hemostasis—MMP1—systemic scleroderma	4.19e-05	0.00092	CbGpPWpGaD
Doxorubicin—Pancytopenia—Methotrexate—systemic scleroderma	4.18e-05	0.000237	CcSEcCtD
Doxorubicin—Feeling abnormal—Lisinopril—systemic scleroderma	4.15e-05	0.000236	CcSEcCtD
Doxorubicin—Pruritus—Leflunomide—systemic scleroderma	4.15e-05	0.000235	CcSEcCtD
Doxorubicin—Connective tissue disorder—Prednisone—systemic scleroderma	4.14e-05	0.000235	CcSEcCtD
Doxorubicin—Hypotension—Mycophenolate mofetil—systemic scleroderma	4.12e-05	0.000234	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Lisinopril—systemic scleroderma	4.12e-05	0.000234	CcSEcCtD
Doxorubicin—Neutropenia—Methotrexate—systemic scleroderma	4.11e-05	0.000233	CcSEcCtD
Doxorubicin—Dysuria—Methotrexate—systemic scleroderma	4.11e-05	0.000233	CcSEcCtD
Doxorubicin—Dizziness—Azathioprine—systemic scleroderma	4.11e-05	0.000233	CcSEcCtD
Doxorubicin—AKR1C3—Disease—HSPG2—systemic scleroderma	4.1e-05	0.0009	CbGpPWpGaD
Doxorubicin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	4.09e-05	0.000232	CcSEcCtD
Doxorubicin—NOS2—Disease—CD247—systemic scleroderma	4.05e-05	0.000889	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—NOS3—systemic scleroderma	4.03e-05	0.000884	CbGpPWpGaD
Doxorubicin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	4.02e-05	0.000228	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Methotrexate—systemic scleroderma	4.01e-05	0.000228	CcSEcCtD
Doxorubicin—Asthenia—Mycophenolic acid—systemic scleroderma	4.01e-05	0.000228	CcSEcCtD
Doxorubicin—Diarrhoea—Leflunomide—systemic scleroderma	4.01e-05	0.000228	CcSEcCtD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4e-05	0.000879	CbGpPWpGaD
Doxorubicin—Urticaria—Lisinopril—systemic scleroderma	4e-05	0.000227	CcSEcCtD
Doxorubicin—Insomnia—Mycophenolate mofetil—systemic scleroderma	3.99e-05	0.000227	CcSEcCtD
Doxorubicin—Abdominal pain—Lisinopril—systemic scleroderma	3.98e-05	0.000226	CcSEcCtD
Doxorubicin—Body temperature increased—Lisinopril—systemic scleroderma	3.98e-05	0.000226	CcSEcCtD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.97e-05	0.000871	CbGpPWpGaD
Doxorubicin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	3.96e-05	0.000225	CcSEcCtD
Doxorubicin—AKR1C3—Disease—CSK—systemic scleroderma	3.96e-05	0.000869	CbGpPWpGaD
Doxorubicin—Pruritus—Mycophenolic acid—systemic scleroderma	3.96e-05	0.000225	CcSEcCtD
Doxorubicin—Vomiting—Azathioprine—systemic scleroderma	3.95e-05	0.000224	CcSEcCtD
Doxorubicin—Pneumonia—Methotrexate—systemic scleroderma	3.94e-05	0.000224	CcSEcCtD
Doxorubicin—Eye disorder—Prednisone—systemic scleroderma	3.94e-05	0.000223	CcSEcCtD
Doxorubicin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	3.94e-05	0.000223	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—SMAD7—systemic scleroderma	3.93e-05	0.000864	CbGpPWpGaD
Doxorubicin—Somnolence—Mycophenolate mofetil—systemic scleroderma	3.92e-05	0.000223	CcSEcCtD
Doxorubicin—Infestation—Methotrexate—systemic scleroderma	3.92e-05	0.000223	CcSEcCtD
Doxorubicin—Drowsiness—Methotrexate—systemic scleroderma	3.92e-05	0.000223	CcSEcCtD
Doxorubicin—Infestation NOS—Methotrexate—systemic scleroderma	3.92e-05	0.000223	CcSEcCtD
Doxorubicin—Rash—Azathioprine—systemic scleroderma	3.91e-05	0.000222	CcSEcCtD
Doxorubicin—Dermatitis—Azathioprine—systemic scleroderma	3.91e-05	0.000222	CcSEcCtD
Doxorubicin—Flushing—Prednisone—systemic scleroderma	3.91e-05	0.000222	CcSEcCtD
Doxorubicin—Headache—Azathioprine—systemic scleroderma	3.89e-05	0.000221	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	3.89e-05	0.000221	CcSEcCtD
Doxorubicin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	3.89e-05	0.000221	CcSEcCtD
Doxorubicin—Dizziness—Leflunomide—systemic scleroderma	3.88e-05	0.00022	CcSEcCtD
Doxorubicin—Renal failure—Methotrexate—systemic scleroderma	3.85e-05	0.000219	CcSEcCtD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.84e-05	0.000842	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.84e-05	0.000842	CbGpPWpGaD
Doxorubicin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	3.84e-05	0.000218	CcSEcCtD
Doxorubicin—Diarrhoea—Mycophenolic acid—systemic scleroderma	3.83e-05	0.000217	CcSEcCtD
Doxorubicin—Stomatitis—Methotrexate—systemic scleroderma	3.82e-05	0.000217	CcSEcCtD
Doxorubicin—Angiopathy—Prednisone—systemic scleroderma	3.82e-05	0.000217	CcSEcCtD
Doxorubicin—Conjunctivitis—Methotrexate—systemic scleroderma	3.81e-05	0.000216	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	3.81e-05	0.000216	CcSEcCtD
Doxorubicin—Immune system disorder—Prednisone—systemic scleroderma	3.8e-05	0.000216	CcSEcCtD
Doxorubicin—Pain—Mycophenolate mofetil—systemic scleroderma	3.77e-05	0.000214	CcSEcCtD
Doxorubicin—Constipation—Mycophenolate mofetil—systemic scleroderma	3.77e-05	0.000214	CcSEcCtD
Doxorubicin—Arrhythmia—Prednisone—systemic scleroderma	3.76e-05	0.000214	CcSEcCtD
Doxorubicin—Sweating—Methotrexate—systemic scleroderma	3.76e-05	0.000213	CcSEcCtD
Doxorubicin—Haematuria—Methotrexate—systemic scleroderma	3.74e-05	0.000212	CcSEcCtD
Doxorubicin—Vomiting—Leflunomide—systemic scleroderma	3.73e-05	0.000212	CcSEcCtD
Doxorubicin—AKR1C3—Disease—CD247—systemic scleroderma	3.72e-05	0.000817	CbGpPWpGaD
Doxorubicin—Alopecia—Prednisone—systemic scleroderma	3.72e-05	0.000211	CcSEcCtD
Doxorubicin—Hypersensitivity—Lisinopril—systemic scleroderma	3.71e-05	0.000211	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Methotrexate—systemic scleroderma	3.71e-05	0.00021	CcSEcCtD
Doxorubicin—Dizziness—Mycophenolic acid—systemic scleroderma	3.7e-05	0.00021	CcSEcCtD
Doxorubicin—Epistaxis—Methotrexate—systemic scleroderma	3.7e-05	0.00021	CcSEcCtD
Doxorubicin—Rash—Leflunomide—systemic scleroderma	3.7e-05	0.00021	CcSEcCtD
Doxorubicin—Dermatitis—Leflunomide—systemic scleroderma	3.69e-05	0.00021	CcSEcCtD
Doxorubicin—Mental disorder—Prednisone—systemic scleroderma	3.69e-05	0.000209	CcSEcCtD
Doxorubicin—Nausea—Azathioprine—systemic scleroderma	3.69e-05	0.000209	CcSEcCtD
Doxorubicin—Headache—Leflunomide—systemic scleroderma	3.67e-05	0.000208	CcSEcCtD
Doxorubicin—Malnutrition—Prednisone—systemic scleroderma	3.67e-05	0.000208	CcSEcCtD
Doxorubicin—Erythema—Prednisone—systemic scleroderma	3.67e-05	0.000208	CcSEcCtD
Doxorubicin—Agranulocytosis—Methotrexate—systemic scleroderma	3.66e-05	0.000208	CcSEcCtD
Doxorubicin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	3.64e-05	0.000206	CcSEcCtD
Doxorubicin—Asthenia—Lisinopril—systemic scleroderma	3.61e-05	0.000205	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	3.61e-05	0.000205	CcSEcCtD
Doxorubicin—Pruritus—Lisinopril—systemic scleroderma	3.56e-05	0.000202	CcSEcCtD
Doxorubicin—NQO1—Metabolism—HSPG2—systemic scleroderma	3.56e-05	0.000781	CbGpPWpGaD
Doxorubicin—Vomiting—Mycophenolic acid—systemic scleroderma	3.56e-05	0.000202	CcSEcCtD
Doxorubicin—Haemoglobin—Methotrexate—systemic scleroderma	3.54e-05	0.000201	CcSEcCtD
Doxorubicin—Rash—Mycophenolic acid—systemic scleroderma	3.53e-05	0.0002	CcSEcCtD
Doxorubicin—Dermatitis—Mycophenolic acid—systemic scleroderma	3.52e-05	0.0002	CcSEcCtD
Doxorubicin—Hepatitis—Methotrexate—systemic scleroderma	3.52e-05	0.0002	CcSEcCtD
Doxorubicin—Haemorrhage—Methotrexate—systemic scleroderma	3.52e-05	0.0002	CcSEcCtD
Doxorubicin—Urticaria—Mycophenolate mofetil—systemic scleroderma	3.51e-05	0.000199	CcSEcCtD
Doxorubicin—Headache—Mycophenolic acid—systemic scleroderma	3.5e-05	0.000199	CcSEcCtD
Doxorubicin—Pharyngitis—Methotrexate—systemic scleroderma	3.49e-05	0.000198	CcSEcCtD
Doxorubicin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	3.49e-05	0.000198	CcSEcCtD
Doxorubicin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	3.49e-05	0.000198	CcSEcCtD
Doxorubicin—Nausea—Leflunomide—systemic scleroderma	3.48e-05	0.000198	CcSEcCtD
Doxorubicin—Urinary tract disorder—Methotrexate—systemic scleroderma	3.48e-05	0.000197	CcSEcCtD
Doxorubicin—NOS3—Disease—HSPG2—systemic scleroderma	3.46e-05	0.00076	CbGpPWpGaD
Doxorubicin—Vision blurred—Prednisone—systemic scleroderma	3.46e-05	0.000196	CcSEcCtD
Doxorubicin—Urethral disorder—Methotrexate—systemic scleroderma	3.45e-05	0.000196	CcSEcCtD
Doxorubicin—Diarrhoea—Lisinopril—systemic scleroderma	3.45e-05	0.000196	CcSEcCtD
Doxorubicin—AKR1C3—Metabolism—HSPG2—systemic scleroderma	3.43e-05	0.000753	CbGpPWpGaD
Doxorubicin—Ill-defined disorder—Prednisone—systemic scleroderma	3.4e-05	0.000193	CcSEcCtD
Doxorubicin—Visual impairment—Methotrexate—systemic scleroderma	3.39e-05	0.000193	CcSEcCtD
Doxorubicin—Anaemia—Prednisone—systemic scleroderma	3.39e-05	0.000192	CcSEcCtD
Doxorubicin—Agitation—Prednisone—systemic scleroderma	3.37e-05	0.000191	CcSEcCtD
Doxorubicin—NOS3—Disease—CSK—systemic scleroderma	3.34e-05	0.000734	CbGpPWpGaD
Doxorubicin—Dizziness—Lisinopril—systemic scleroderma	3.33e-05	0.000189	CcSEcCtD
Doxorubicin—Erythema multiforme—Methotrexate—systemic scleroderma	3.33e-05	0.000189	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—SMAD7—systemic scleroderma	3.32e-05	0.00073	CbGpPWpGaD
Doxorubicin—Nausea—Mycophenolic acid—systemic scleroderma	3.32e-05	0.000189	CcSEcCtD
Doxorubicin—Malaise—Prednisone—systemic scleroderma	3.31e-05	0.000188	CcSEcCtD
Doxorubicin—Vertigo—Prednisone—systemic scleroderma	3.29e-05	0.000187	CcSEcCtD
Doxorubicin—Eye disorder—Methotrexate—systemic scleroderma	3.29e-05	0.000187	CcSEcCtD
Doxorubicin—Syncope—Prednisone—systemic scleroderma	3.29e-05	0.000187	CcSEcCtD
Doxorubicin—Tinnitus—Methotrexate—systemic scleroderma	3.28e-05	0.000186	CcSEcCtD
Doxorubicin—ABCC3—NRF2 pathway—TGFB1—systemic scleroderma	3.28e-05	0.00072	CbGpPWpGaD
Doxorubicin—Cardiac disorder—Methotrexate—systemic scleroderma	3.27e-05	0.000185	CcSEcCtD
Doxorubicin—NOS3—Hemostasis—MMP1—systemic scleroderma	3.26e-05	0.000714	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	3.25e-05	0.000185	CcSEcCtD
Doxorubicin—Loss of consciousness—Prednisone—systemic scleroderma	3.22e-05	0.000183	CcSEcCtD
Doxorubicin—Vomiting—Lisinopril—systemic scleroderma	3.2e-05	0.000182	CcSEcCtD
Doxorubicin—Angiopathy—Methotrexate—systemic scleroderma	3.19e-05	0.000181	CcSEcCtD
Doxorubicin—XDH—Metabolism—HSPG2—systemic scleroderma	3.19e-05	0.0007	CbGpPWpGaD
Doxorubicin—Immune system disorder—Methotrexate—systemic scleroderma	3.18e-05	0.00018	CcSEcCtD
Doxorubicin—Rash—Lisinopril—systemic scleroderma	3.18e-05	0.00018	CcSEcCtD
Doxorubicin—Convulsion—Prednisone—systemic scleroderma	3.18e-05	0.00018	CcSEcCtD
Doxorubicin—Dermatitis—Lisinopril—systemic scleroderma	3.17e-05	0.00018	CcSEcCtD
Doxorubicin—Mediastinal disorder—Methotrexate—systemic scleroderma	3.17e-05	0.00018	CcSEcCtD
Doxorubicin—Asthenia—Mycophenolate mofetil—systemic scleroderma	3.17e-05	0.00018	CcSEcCtD
Doxorubicin—Hypertension—Prednisone—systemic scleroderma	3.17e-05	0.00018	CcSEcCtD
Doxorubicin—Chills—Methotrexate—systemic scleroderma	3.16e-05	0.000179	CcSEcCtD
Doxorubicin—Headache—Lisinopril—systemic scleroderma	3.16e-05	0.000179	CcSEcCtD
Doxorubicin—NOS3—Disease—CD247—systemic scleroderma	3.14e-05	0.00069	CbGpPWpGaD
Doxorubicin—Pruritus—Mycophenolate mofetil—systemic scleroderma	3.12e-05	0.000177	CcSEcCtD
Doxorubicin—Myalgia—Prednisone—systemic scleroderma	3.12e-05	0.000177	CcSEcCtD
Doxorubicin—Arthralgia—Prednisone—systemic scleroderma	3.12e-05	0.000177	CcSEcCtD
Doxorubicin—Anxiety—Prednisone—systemic scleroderma	3.11e-05	0.000177	CcSEcCtD
Doxorubicin—Alopecia—Methotrexate—systemic scleroderma	3.11e-05	0.000177	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	3.1e-05	0.000176	CcSEcCtD
Doxorubicin—Discomfort—Prednisone—systemic scleroderma	3.08e-05	0.000175	CcSEcCtD
Doxorubicin—Mental disorder—Methotrexate—systemic scleroderma	3.08e-05	0.000175	CcSEcCtD
Doxorubicin—Erythema—Methotrexate—systemic scleroderma	3.06e-05	0.000174	CcSEcCtD
Doxorubicin—Malnutrition—Methotrexate—systemic scleroderma	3.06e-05	0.000174	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—RHOB—systemic scleroderma	3.04e-05	0.000668	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—NOS3—systemic scleroderma	3.04e-05	0.000667	CbGpPWpGaD
Doxorubicin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	3.02e-05	0.000171	CcSEcCtD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.01e-05	0.00066	CbGpPWpGaD
Doxorubicin—Dysgeusia—Methotrexate—systemic scleroderma	3e-05	0.00017	CcSEcCtD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3e-05	0.000657	CbGpPWpGaD
Doxorubicin—Nausea—Lisinopril—systemic scleroderma	2.99e-05	0.00017	CcSEcCtD
Doxorubicin—Anaphylactic shock—Prednisone—systemic scleroderma	2.99e-05	0.00017	CcSEcCtD
Doxorubicin—Oedema—Prednisone—systemic scleroderma	2.99e-05	0.00017	CcSEcCtD
Doxorubicin—Infection—Prednisone—systemic scleroderma	2.97e-05	0.000169	CcSEcCtD
Doxorubicin—Back pain—Methotrexate—systemic scleroderma	2.96e-05	0.000168	CcSEcCtD
Doxorubicin—Shock—Prednisone—systemic scleroderma	2.94e-05	0.000167	CcSEcCtD
Doxorubicin—Nervous system disorder—Prednisone—systemic scleroderma	2.93e-05	0.000167	CcSEcCtD
Doxorubicin—Tachycardia—Prednisone—systemic scleroderma	2.92e-05	0.000166	CcSEcCtD
Doxorubicin—Dizziness—Mycophenolate mofetil—systemic scleroderma	2.92e-05	0.000166	CcSEcCtD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.91e-05	0.000638	CbGpPWpGaD
Doxorubicin—Skin disorder—Prednisone—systemic scleroderma	2.91e-05	0.000165	CcSEcCtD
Doxorubicin—NOS3—Metabolism—HSPG2—systemic scleroderma	2.9e-05	0.000637	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SMAD7—systemic scleroderma	2.89e-05	0.000635	CbGpPWpGaD
Doxorubicin—Hyperhidrosis—Prednisone—systemic scleroderma	2.89e-05	0.000164	CcSEcCtD
Doxorubicin—Vision blurred—Methotrexate—systemic scleroderma	2.89e-05	0.000164	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—HSPG2—systemic scleroderma	2.87e-05	0.00063	CbGpPWpGaD
Doxorubicin—Anorexia—Prednisone—systemic scleroderma	2.85e-05	0.000162	CcSEcCtD
Doxorubicin—Ill-defined disorder—Methotrexate—systemic scleroderma	2.84e-05	0.000161	CcSEcCtD
Doxorubicin—Anaemia—Methotrexate—systemic scleroderma	2.83e-05	0.000161	CcSEcCtD
Doxorubicin—Vomiting—Mycophenolate mofetil—systemic scleroderma	2.81e-05	0.000159	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—EDN1—systemic scleroderma	2.8e-05	0.000616	CbGpPWpGaD
Doxorubicin—Rash—Mycophenolate mofetil—systemic scleroderma	2.78e-05	0.000158	CcSEcCtD
Doxorubicin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	2.78e-05	0.000158	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—CSK—systemic scleroderma	2.77e-05	0.000608	CbGpPWpGaD
Doxorubicin—Headache—Mycophenolate mofetil—systemic scleroderma	2.77e-05	0.000157	CcSEcCtD
Doxorubicin—Malaise—Methotrexate—systemic scleroderma	2.76e-05	0.000157	CcSEcCtD
Doxorubicin—Vertigo—Methotrexate—systemic scleroderma	2.75e-05	0.000156	CcSEcCtD
Doxorubicin—Leukopenia—Methotrexate—systemic scleroderma	2.74e-05	0.000156	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.73e-05	0.000155	CcSEcCtD
Doxorubicin—Insomnia—Prednisone—systemic scleroderma	2.71e-05	0.000154	CcSEcCtD
Doxorubicin—NQO1—Metabolism—CTGF—systemic scleroderma	2.7e-05	0.000592	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—NOS3—systemic scleroderma	2.7e-05	0.000592	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—NOS3—systemic scleroderma	2.7e-05	0.000592	CbGpPWpGaD
Doxorubicin—Paraesthesia—Prednisone—systemic scleroderma	2.69e-05	0.000152	CcSEcCtD
Doxorubicin—Cough—Methotrexate—systemic scleroderma	2.67e-05	0.000152	CcSEcCtD
Doxorubicin—NOS1—Hemostasis—TGFB1—systemic scleroderma	2.66e-05	0.000585	CbGpPWpGaD
Doxorubicin—Convulsion—Methotrexate—systemic scleroderma	2.65e-05	0.000151	CcSEcCtD
Doxorubicin—ABCC1—Disease—TGFBI—systemic scleroderma	2.65e-05	0.000581	CbGpPWpGaD
Doxorubicin—Dyspepsia—Prednisone—systemic scleroderma	2.63e-05	0.000149	CcSEcCtD
Doxorubicin—Nausea—Mycophenolate mofetil—systemic scleroderma	2.62e-05	0.000149	CcSEcCtD
Doxorubicin—Myalgia—Methotrexate—systemic scleroderma	2.61e-05	0.000148	CcSEcCtD
Doxorubicin—Arthralgia—Methotrexate—systemic scleroderma	2.61e-05	0.000148	CcSEcCtD
Doxorubicin—Chest pain—Methotrexate—systemic scleroderma	2.61e-05	0.000148	CcSEcCtD
Doxorubicin—AKR1C3—Metabolism—CTGF—systemic scleroderma	2.6e-05	0.000571	CbGpPWpGaD
Doxorubicin—Decreased appetite—Prednisone—systemic scleroderma	2.6e-05	0.000148	CcSEcCtD
Doxorubicin—ABCC2—NRF2 pathway—TGFB1—systemic scleroderma	2.6e-05	0.000571	CbGpPWpGaD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	2.59e-05	0.000147	CcSEcCtD
Doxorubicin—Fatigue—Prednisone—systemic scleroderma	2.58e-05	0.000146	CcSEcCtD
Doxorubicin—Discomfort—Methotrexate—systemic scleroderma	2.58e-05	0.000146	CcSEcCtD
Doxorubicin—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	2.57e-05	0.000564	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—RHOB—systemic scleroderma	2.57e-05	0.000564	CbGpPWpGaD
Doxorubicin—Constipation—Prednisone—systemic scleroderma	2.56e-05	0.000145	CcSEcCtD
Doxorubicin—NDUFS2—Metabolism—NOS3—systemic scleroderma	2.54e-05	0.000556	CbGpPWpGaD
Doxorubicin—Confusional state—Methotrexate—systemic scleroderma	2.52e-05	0.000143	CcSEcCtD
Doxorubicin—Anaphylactic shock—Methotrexate—systemic scleroderma	2.5e-05	0.000142	CcSEcCtD
Doxorubicin—Infection—Methotrexate—systemic scleroderma	2.48e-05	0.000141	CcSEcCtD
Doxorubicin—Feeling abnormal—Prednisone—systemic scleroderma	2.47e-05	0.00014	CcSEcCtD
Doxorubicin—Nervous system disorder—Methotrexate—systemic scleroderma	2.45e-05	0.000139	CcSEcCtD
Doxorubicin—Thrombocytopenia—Methotrexate—systemic scleroderma	2.45e-05	0.000139	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Prednisone—systemic scleroderma	2.45e-05	0.000139	CcSEcCtD
Doxorubicin—Skin disorder—Methotrexate—systemic scleroderma	2.43e-05	0.000138	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—HSPG2—systemic scleroderma	2.43e-05	0.000532	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—CTGF—systemic scleroderma	2.42e-05	0.000531	CbGpPWpGaD
Doxorubicin—Hyperhidrosis—Methotrexate—systemic scleroderma	2.42e-05	0.000137	CcSEcCtD
Doxorubicin—Anorexia—Methotrexate—systemic scleroderma	2.38e-05	0.000135	CcSEcCtD
Doxorubicin—Urticaria—Prednisone—systemic scleroderma	2.38e-05	0.000135	CcSEcCtD
Doxorubicin—Body temperature increased—Prednisone—systemic scleroderma	2.37e-05	0.000134	CcSEcCtD
Doxorubicin—Abdominal pain—Prednisone—systemic scleroderma	2.37e-05	0.000134	CcSEcCtD
Doxorubicin—ABCB11—Metabolism—HSPG2—systemic scleroderma	2.35e-05	0.000516	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CSK—systemic scleroderma	2.34e-05	0.000514	CbGpPWpGaD
Doxorubicin—Hypotension—Methotrexate—systemic scleroderma	2.34e-05	0.000133	CcSEcCtD
Doxorubicin—TOP2A—Methyltestosterone—Prednisone—systemic scleroderma	2.33e-05	0.00719	CbGdCrCtD
Doxorubicin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	2.28e-05	0.000129	CcSEcCtD
Doxorubicin—Insomnia—Methotrexate—systemic scleroderma	2.26e-05	0.000128	CcSEcCtD
Doxorubicin—ABCC3—Metabolism—HSPG2—systemic scleroderma	2.26e-05	0.000495	CbGpPWpGaD
Doxorubicin—Paraesthesia—Methotrexate—systemic scleroderma	2.25e-05	0.000127	CcSEcCtD
Doxorubicin—Dyspnoea—Methotrexate—systemic scleroderma	2.23e-05	0.000127	CcSEcCtD
Doxorubicin—Somnolence—Methotrexate—systemic scleroderma	2.22e-05	0.000126	CcSEcCtD
Doxorubicin—Hypersensitivity—Prednisone—systemic scleroderma	2.2e-05	0.000125	CcSEcCtD
Doxorubicin—Dyspepsia—Methotrexate—systemic scleroderma	2.2e-05	0.000125	CcSEcCtD
Doxorubicin—NOS3—Metabolism—CTGF—systemic scleroderma	2.2e-05	0.000482	CbGpPWpGaD
Doxorubicin—Decreased appetite—Methotrexate—systemic scleroderma	2.17e-05	0.000123	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	2.16e-05	0.000123	CcSEcCtD
Doxorubicin—Fatigue—Methotrexate—systemic scleroderma	2.16e-05	0.000122	CcSEcCtD
Doxorubicin—DHCR7—Metabolism—NOS3—systemic scleroderma	2.16e-05	0.000473	CbGpPWpGaD
Doxorubicin—Asthenia—Prednisone—systemic scleroderma	2.15e-05	0.000122	CcSEcCtD
Doxorubicin—Pain—Methotrexate—systemic scleroderma	2.14e-05	0.000121	CcSEcCtD
Doxorubicin—Pruritus—Prednisone—systemic scleroderma	2.12e-05	0.00012	CcSEcCtD
Doxorubicin—ABCC1—Disease—HSPG2—systemic scleroderma	2.11e-05	0.000463	CbGpPWpGaD
Doxorubicin—Feeling abnormal—Methotrexate—systemic scleroderma	2.06e-05	0.000117	CcSEcCtD
Doxorubicin—Diarrhoea—Prednisone—systemic scleroderma	2.05e-05	0.000116	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.04e-05	0.000116	CcSEcCtD
Doxorubicin—ABCC1—Disease—CSK—systemic scleroderma	2.04e-05	0.000447	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—NOS3—systemic scleroderma	2.01e-05	0.000441	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—TGFB1—systemic scleroderma	2.01e-05	0.000441	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	2e-05	0.000439	CbGpPWpGaD
Doxorubicin—Urticaria—Methotrexate—systemic scleroderma	1.99e-05	0.000113	CcSEcCtD
Doxorubicin—Dizziness—Prednisone—systemic scleroderma	1.98e-05	0.000112	CcSEcCtD
Doxorubicin—Abdominal pain—Methotrexate—systemic scleroderma	1.98e-05	0.000112	CcSEcCtD
Doxorubicin—Body temperature increased—Methotrexate—systemic scleroderma	1.98e-05	0.000112	CcSEcCtD
Doxorubicin—NOS1—Disease—NOS3—systemic scleroderma	1.95e-05	0.000428	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CCL2—systemic scleroderma	1.92e-05	0.000421	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CD247—systemic scleroderma	1.92e-05	0.000421	CbGpPWpGaD
Doxorubicin—Vomiting—Prednisone—systemic scleroderma	1.9e-05	0.000108	CcSEcCtD
Doxorubicin—Rash—Prednisone—systemic scleroderma	1.89e-05	0.000107	CcSEcCtD
Doxorubicin—Dermatitis—Prednisone—systemic scleroderma	1.88e-05	0.000107	CcSEcCtD
Doxorubicin—Headache—Prednisone—systemic scleroderma	1.87e-05	0.000106	CcSEcCtD
Doxorubicin—Hypersensitivity—Methotrexate—systemic scleroderma	1.84e-05	0.000105	CcSEcCtD
Doxorubicin—Asthenia—Methotrexate—systemic scleroderma	1.79e-05	0.000102	CcSEcCtD
Doxorubicin—ABCB11—Metabolism—CTGF—systemic scleroderma	1.78e-05	0.000391	CbGpPWpGaD
Doxorubicin—Nausea—Prednisone—systemic scleroderma	1.78e-05	0.000101	CcSEcCtD
Doxorubicin—Pruritus—Methotrexate—systemic scleroderma	1.77e-05	0.0001	CcSEcCtD
Doxorubicin—ABCC1—Metabolism—HSPG2—systemic scleroderma	1.77e-05	0.000388	CbGpPWpGaD
Doxorubicin—Diarrhoea—Methotrexate—systemic scleroderma	1.71e-05	9.71e-05	CcSEcCtD
Doxorubicin—ABCC3—Metabolism—CTGF—systemic scleroderma	1.71e-05	0.000375	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—HSPG2—systemic scleroderma	1.71e-05	0.000375	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—NOS3—systemic scleroderma	1.71e-05	0.000375	CbGpPWpGaD
Doxorubicin—Dizziness—Methotrexate—systemic scleroderma	1.65e-05	9.38e-05	CcSEcCtD
Doxorubicin—Vomiting—Methotrexate—systemic scleroderma	1.59e-05	9.02e-05	CcSEcCtD
Doxorubicin—Rash—Methotrexate—systemic scleroderma	1.58e-05	8.95e-05	CcSEcCtD
Doxorubicin—Dermatitis—Methotrexate—systemic scleroderma	1.58e-05	8.94e-05	CcSEcCtD
Doxorubicin—Headache—Methotrexate—systemic scleroderma	1.57e-05	8.89e-05	CcSEcCtD
Doxorubicin—NOS3—Hemostasis—TGFB1—systemic scleroderma	1.56e-05	0.000342	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—HSPG2—systemic scleroderma	1.56e-05	0.000341	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EDN1—systemic scleroderma	1.55e-05	0.000341	CbGpPWpGaD
Doxorubicin—Nausea—Methotrexate—systemic scleroderma	1.49e-05	8.43e-05	CcSEcCtD
Doxorubicin—NOS2—Disease—NOS3—systemic scleroderma	1.47e-05	0.000323	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—MMP9—systemic scleroderma	1.37e-05	0.000301	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—NOS3—systemic scleroderma	1.35e-05	0.000297	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CTGF—systemic scleroderma	1.34e-05	0.000294	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EDN1—systemic scleroderma	1.31e-05	0.000288	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CTGF—systemic scleroderma	1.3e-05	0.000284	CbGpPWpGaD
Doxorubicin—NOS1—Disease—TGFB1—systemic scleroderma	1.29e-05	0.000283	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CTGF—systemic scleroderma	1.18e-05	0.000259	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—NOS3—systemic scleroderma	1.17e-05	0.000258	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—HSPG2—systemic scleroderma	1.14e-05	0.00025	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—NOS3—systemic scleroderma	1.13e-05	0.000249	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TGFB1—systemic scleroderma	1.13e-05	0.000248	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCL2—systemic scleroderma	1.06e-05	0.000233	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—NOS3—systemic scleroderma	1.05e-05	0.000231	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	9.86e-06	0.000216	CbGpPWpGaD
Doxorubicin—NOS2—Disease—TGFB1—systemic scleroderma	9.73e-06	0.000214	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NOS3—systemic scleroderma	9.47e-06	0.000208	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCL2—systemic scleroderma	8.98e-06	0.000197	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—TGFB1—systemic scleroderma	8.94e-06	0.000196	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CTGF—systemic scleroderma	8.64e-06	0.00019	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—HSPG2—systemic scleroderma	8.41e-06	0.000185	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—HSPG2—systemic scleroderma	7.92e-06	0.000174	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—NOS3—systemic scleroderma	7.76e-06	0.00017	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MMP9—systemic scleroderma	7.6e-06	0.000167	CbGpPWpGaD
Doxorubicin—NOS3—Disease—TGFB1—systemic scleroderma	7.55e-06	0.000166	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—NOS3—systemic scleroderma	7.44e-06	0.000163	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NOS3—systemic scleroderma	6.96e-06	0.000153	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MMP9—systemic scleroderma	6.42e-06	0.000141	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CTGF—systemic scleroderma	6.37e-06	0.00014	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TGFB1—systemic scleroderma	6.26e-06	0.000137	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CTGF—systemic scleroderma	6e-06	0.000132	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—NOS3—systemic scleroderma	5.83e-06	0.000128	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—NOS3—systemic scleroderma	5.64e-06	0.000124	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TGFB1—systemic scleroderma	5.29e-06	0.000116	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HSPG2—systemic scleroderma	5.18e-06	0.000114	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NOS3—systemic scleroderma	5.13e-06	0.000113	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TGFB1—systemic scleroderma	4.6e-06	0.000101	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CTGF—systemic scleroderma	3.93e-06	8.62e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—NOS3—systemic scleroderma	3.76e-06	8.25e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NOS3—systemic scleroderma	2.77e-06	6.09e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NOS3—systemic scleroderma	2.61e-06	5.74e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.71e-06	3.75e-05	CbGpPWpGaD
